<DOC>
	<DOCNO>NCT02968173</DOCNO>
	<brief_summary>This Phase 3b , prospective , multicenter , open-label , non-controlled study ass safety effectiveness immunoprophylaxis intramuscular ( IM ) administration liquid formulation palivizumab prevention RSV hospitalization infant high risk ( infant bear less equal 35 week gestational age less equal 6 month age enrollment ; infant less equal 24 month age diagnosis chronic lung disease [ CLD ] prematurity require on-going medical treatment within previous 6 month infant less equal 24 month age hemodynamically significant congenital heart disease [ CHD ] ) .</brief_summary>
	<brief_title>A Study Assess Safety Effectiveness Palivizumab Administered Children High Risk Severe Respiratory Syncytial Virus ( RSV ) Infection Russian Federation Republic Belarus</brief_title>
	<detailed_description>Participants receive palivizumab solution injection 15 mg/kg IM injection every 30 day minimum 3 maximum 5 injection give anticipated period RSV risk community ; number dose depend time enrollment RSV season .</detailed_description>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>Infants high risk severe RSV infection define fulfil least one following : Infants bear ≤ 35 week gestational age AND ≤ 6 month age enrollment ; Infants ≤ 24 month age enrollment AND diagnosis bronchopulmonary dysplasia ( BPD ) ( define oxygen requirement correct gestational age 36 week ) require intervention/management ( i.e. , oxygen , diuretic , bronchodilator , corticosteroid , etc . ) anytime within 6 month prior enrollment ; Infants ≤ 24 month age enrollment hemodynamically significant congenital heart disease ( CHD ) , either cyanotic acyanotic , unoperated partially correct . Children acyanotic cardiac lesion must pulmonary hypertension ( ≥ 40 mmHg measure pressure pulmonary artery [ ultrasound acceptable ] ) need daily medication manage CHD . Hospitalization time enrollment ( unless discharge anticipate within 14 day ) . Mechanical ventilation ( include continuous positive airway pressure , CPAP ) time enrollment . Life expectancy le 6 month . Unstable cardiac respiratory status , include cardiac defect severe survival expect cardiac transplantation plan anticipate . Active respiratory illness , acute infection .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Bronchopulmonary dysplasia ( BPD )</keyword>
	<keyword>RSV hospitalization</keyword>
	<keyword>Palivizumab</keyword>
	<keyword>Immunoprophylaxis</keyword>
	<keyword>Chronic lung disease ( CLD ) prematurity</keyword>
</DOC>